This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.


Feuerstein graduated from Emory University with a bachelor's degree in political science.


Adam Feuerstein
By This Author:
Page 2 of 16

The Next Big Thing In Biotech: Titan

By Adam Feuerstein

Titan Pharmaceuticals is the next big thing in biotech, Adam Feuerstein, Sr. Columnist for TheStreet, tells Gregg Greenberg

12:02PM 03/14/13

The Next Big Thing In Biotech: Onyx

By Adam Feuerstein

Adam Feuerstein, Sr. Columnist at TheStreet, tells Gregg Greenberg why Onyx Pharmaceuticals is the next big thing in biotech.

01:11PM 03/07/13

The Next Big Thing In Biotech: DepoMed

By Adam Feuerstein

Adam Feuerstein, Sr. Columnist at TheStreet, says DepoMed is the next big thing in biotech.

09:42AM 02/28/13

The Next Big Thing In Biotech: BIO CEO Conference

By Adam Feuerstein

Adam Feuerstein, Sr. Columnist for TheStreet, says the BIO CEO Conference is the next big thing in biotech.

11:38AM 02/07/13

The Next Big Thing In Biotech: Gilead

By Adam Feuerstein

Adam Feuerstein, Sr. Columnist for TheStreet, says Gilead Sciences is the next big thing in biotech.

07:21AM 02/01/13

The Next Big Thing in Biotech: Celgene

By Adam Feuerstein

Senior columnist Adam Feuerstein says Celgene is the next big thing in biotech.

05:30AM 01/18/13

The Next Big Thing in Biotech: J.P. Morgan Conference

By Adam Feuerstein

Adam Feuerstein, senior columnist for TheStreet, says the coming week's J.P. Morgan Healthcare Conference is the next big thing in biotech.

05:00AM 01/04/13

The Next Big Thing In Biotech: 2013 Outlook

By Adam Feuerstein

Adam Feuerstein, Sr. Columnist for TheStreet, offers his outlook for the best and worst biotech stock in the coming year.

05:30AM 12/21/12

The Next Big Thing in Biotech: FDA Decisions

By Adam Feuerstein

Senior columnist Adam Feuerstein says three big FDA drug approval decisions are the next big things to watch in biotech.

05:30AM 12/14/12

The Next Big Thing In Biotech: ASH Meeting

By Adam Feuerstein

Adam Feuerstein, Sr. Columnist for TheStreet, says the American Society of Hematology meeting is the next big thing to watch in biotech.

06:00AM 12/07/12

Page 2 of 16

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs